Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Overview
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Adastra Pharmaceuticals Inc
Apollo Therapeutics LLC
Arc Therapeutics Inc
Astex Pharmaceuticals Inc
Cyclacel Pharmaceuticals Inc
Neosome Life Sciences LLC
Nuvation Bio Inc
Pfizer Inc
Prous Institute for Biomedical Research SA
Rizen (Suzhou) Biosciences Co Ltd
Shanghai Junshi Bioscience Co Ltd
Tizia Life Sciences Plc
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Drug Profiles
AT-7519 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-68127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ebvaciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fadraciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JRP-890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JS-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JS-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
kenpaullone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
milciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEOS-518 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NUV-422 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-07104091 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sapacitabine + seliciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seliciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zotiraciclib citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kise 2 (p33 Protein Kise or Cell Division Protein Kise 2 or CDK2 or EC 2.7.11.22) - Product Development Milestones
Featured News & Press Releases
Oct 26, 2020: Cyclacel presents phase 1 clinical data showing safety, anti-tumor activity and good oral bioavailability of fadraciclib in patients with advanced solid tumors at the EORTC-NCI-AACR Symposium 2020
Oct 13, 2020: Nuvation Bio announces FDA acceptance of investigatiol new drug (IND) application for NUV-422 for treatment of patients with high-grade gliomas
Oct 06, 2020: ICR to study fadraciclib to treat paediatric neuroblastoma
Sep 21, 2020: Cyclacel announces Fadraciclib abstract selected for oral presentation in the Late Breaking and Best Proffered Paper session at the 32nd EORTC-NCI-AACR Symposium 2020
Aug 21, 2020: Tizia granted a patent on the use of milciclib in combition with tyrosine kise inhibitors for treatment of hepatocellular carcinoma and other cancers
Jul 13, 2020: Cyclacel’s clinical stage CDK2/9 inhibitor Fadraciclib targets key anti-apoptotic and oncogenic pathways in cancer
May 14, 2020: Tizia Lifesciences announces online publication of two abstracts at the American Society of Clinical Oncology (ASCO) reporting clinical activity and safety of Milciclib in patients with advanced hepatocellular carcinoma
May 11, 2020: Tizia Life Sciences announces publishing of two e-abstracts featuring its Miliciclib
Dec 09, 2019: Cyclacel’s CYC065 and Venetoclax demonstrate therapeutic potential and anticancer activity in acute myeloid and chronic lymphocytic leukemias
Nov 06, 2019: Cyclacel Pharmaceuticals announces multiple clinical abstracts on CYC065 selected for presentation at the ASH 2019 Annual Meeting
Sep 09, 2019: Cyclacel Pharmaceuticals announces first patient treated with oral CYC065 in a phase 1 study in patients with advanced solid tumors
Sep 04, 2019: Tizia Life Sciences -phase 2a clinical data
Sep 04, 2019: Adastra Pharmaceuticals to present at the 2019 Janney Healthcare Conference
Jul 24, 2019: Tizia reveals positive results for Milciclib in liver cancer trial
Jul 22, 2019: Tizia reports phase 2a clinical data with milciclib monotherapy in Sorafenib-refractory or -intolerant patients with unresectable or metastatic Hepatocellular Carcinoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Products under Development by Companies, H2 2020 (Contd..3), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Adastra Pharmaceuticals Inc, H2 2020
Pipeline by Apollo Therapeutics LLC, H2 2020
Pipeline by Arc Therapeutics Inc, H2 2020
Pipeline by Astex Pharmaceuticals Inc, H2 2020
Pipeline by Cyclacel Pharmaceuticals Inc, H2 2020
Pipeline by Neosome Life Sciences LLC, H2 2020
Pipeline by Nuvation Bio Inc, H2 2020
Pipeline by Pfizer Inc, H2 2020
Pipeline by Prous Institute for Biomedical Research SA, H2 2020
Pipeline by Rizen (Suzhou) Biosciences Co Ltd, H2 2020
Pipeline by Shanghai Junshi Bioscience Co Ltd, H2 2020
Pipeline by Tiziana Life Sciences Plc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Dormant Products, H2 2020 (Contd..2), H2 2020
Discontinued Products, H2 2020